NCT03962010View on ClinicalTrials.gov

A Phase 2, 12-Week, Double-Blind, Efficacy and Safety of GX-G6 in Patients With Uncontrolled Type 2 Diabetes Mellitus

PHASE2UnknownINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

June 1, 2019

Primary Completion Date

June 1, 2022

Study Completion Date

July 1, 2022

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

GX-G6

long acting anti-diabetic drug

DRUG

Control

Control

Sponsors

Lead Sponsor

Genexine, Inc.
All Listed Sponsors
lead

Genexine, Inc.

INDUSTRY

NCT03962010 - A Phase 2, 12-Week, Double-Blind, Efficacy and Safety of GX-G6 in Patients With Uncontrolled Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter